ARTICLE | Clinical News
Strimvelis regulatory update
April 11, 2016 7:00 AM UTC
EMA’s CHMP recommended Strimvelis from GlaxoSmithKline to treat severe combined immunodeficiency (SCID) due to adenosine deaminase deficiency (ADA-SCID) for use in patients for whom a matched bone mar...